Mayne Pharma Group Ltd (MYX) - Cash Flow Conversion Efficiency

Latest as of June 2025: 0.086x

Based on the latest financial reports, Mayne Pharma Group Ltd (MYX) has a cash flow conversion efficiency ratio of 0.086x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$31.98 Million ≈ $22.63 Million USD) by net assets (AU$370.28 Million ≈ $262.00 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Mayne Pharma Group Ltd balance sheet quality to measure how much of total assets are equity-financed.

Mayne Pharma Group Ltd - Cash Flow Conversion Efficiency Trend (2007–2025)

This chart illustrates how Mayne Pharma Group Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Mayne Pharma Group Ltd (MYX) cash earnings ratio to evaluate the quality of earnings relative to operating cash generation.

Mayne Pharma Group Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Mayne Pharma Group Ltd ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
LG Household & Healthcare Ltd Pref
KO:051905
0.029x
Mineralbrunnen Überkingen-Teinach GmbH & Co. KGaA
F:MUT
0.033x
Daewon Sanup Co. Ltd
KQ:005710
-0.021x
Brazil Potash Corp.
NYSE:GRO
-0.027x
Naturhouse Health SA
MC:NTH
0.224x
Kss Line
KO:044450
0.044x
Shinhan Seobu T&D REIT Co Ltd
KO:404990
N/A
Ecomate Holdings Bhd
KLSE:0239
-0.103x

Annual Cash Flow Conversion Efficiency for Mayne Pharma Group Ltd (2007–2025)

The table below shows the annual cash flow conversion efficiency of Mayne Pharma Group Ltd from 2007 to 2025. For the full company profile with market capitalisation and key ratios, see how much is Mayne Pharma Group Ltd worth.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2025-06-30 AU$370.28 Million
≈ $262.00 Million
AU$17.47 Million
≈ $12.36 Million
0.047x +240.05%
2024-06-30 AU$454.19 Million
≈ $321.37 Million
AU$-15.30 Million
≈ $-10.83 Million
-0.034x +49.97%
2023-06-30 AU$634.36 Million
≈ $448.85 Million
AU$-42.71 Million
≈ $-30.22 Million
-0.067x -420.56%
2022-06-30 AU$557.12 Million
≈ $394.20 Million
AU$-7.21 Million
≈ $-5.10 Million
-0.013x -121.12%
2021-06-30 AU$771.58 Million
≈ $545.94 Million
AU$47.26 Million
≈ $33.44 Million
0.061x -36.02%
2020-06-30 AU$1.04 Billion
≈ $737.50 Million
AU$99.78 Million
≈ $70.60 Million
0.096x -8.94%
2019-06-30 AU$1.01 Billion
≈ $717.52 Million
AU$106.61 Million
≈ $75.43 Million
0.105x +6.87%
2018-06-30 AU$1.24 Billion
≈ $873.95 Million
AU$121.50 Million
≈ $85.97 Million
0.098x +947.27%
2017-06-30 AU$1.31 Billion
≈ $928.62 Million
AU$-15.24 Million
≈ $-10.78 Million
-0.012x -108.16%
2016-06-30 AU$376.22 Million
≈ $266.20 Million
AU$53.50 Million
≈ $37.86 Million
0.142x +104.38%
2015-06-30 AU$322.20 Million
≈ $227.98 Million
AU$22.42 Million
≈ $15.86 Million
0.070x -57.60%
2014-06-30 AU$159.27 Million
≈ $112.70 Million
AU$26.14 Million
≈ $18.49 Million
0.164x +189.81%
2013-06-30 AU$120.89 Million
≈ $85.54 Million
AU$6.84 Million
≈ $4.84 Million
0.057x -87.06%
2012-06-30 AU$30.60 Million
≈ $21.65 Million
AU$13.39 Million
≈ $9.47 Million
0.437x +158.83%
2011-06-30 AU$24.17 Million
≈ $17.10 Million
AU$4.09 Million
≈ $2.89 Million
0.169x -57.89%
2010-06-30 AU$25.55 Million
≈ $18.08 Million
AU$10.26 Million
≈ $7.26 Million
0.401x +186.15%
2009-06-30 AU$7.70 Million
≈ $5.45 Million
AU$-3.59 Million
≈ $-2.54 Million
-0.466x -76.14%
2008-06-30 AU$11.44 Million
≈ $8.09 Million
AU$-3.03 Million
≈ $-2.14 Million
-0.265x -209.97%
2007-06-30 AU$14.51 Million
≈ $10.27 Million
AU$-1.24 Million
≈ $-876.47K
-0.085x --

About Mayne Pharma Group Ltd

AU:MYX Australia Medical Distribution
Market Cap
$152.91 Million
AU$216.11 Million AUD
Market Cap Rank
#17529 Global
#510 in Australia
Share Price
AU$2.66
Change (1 day)
+2.31%
52-Week Range
AU$2.13 - AU$6.30
All Time High
AU$41.75
About

Mayne Pharma Group Limited, a specialty pharmaceutical company, focuses on the commercialization of women's health and dermatology pharmaceuticals in Australia, New Zealand, the United States, Canada, Europe, Asia, and internationally. It operates through three segments: Women's Health, Dermatology, and International. The company provides oral drug delivery systems, as well as contract developmen… Read more